Physician profile
Thomas Jiang
NPI 1861719486
$5,053.55
in general payments reported to CMS, 2019-2025
31 companies · $429 in 2025
The $429 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $513 · 2020: $957 · 2021: $1,130 · 2022: $1,198 · 2023: $671 · 2024: $155 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,255.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,392.58 | 2019-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $614.51 | 2021-2023 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $588.65 | 2019-2023 | Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $476.47 | 2019-2025 | Tezspire, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $394.94 | 2019-2022 | |
| Amgen INC. | $235.27 | 2020-2025 | Tezspire |
| Insmed, INC. | $149.68 | 2020-2025 | Arikayce |
| Janssen Biotech, INC. | $143.30 | 2020-2022 | |
| Ethicon INC. | $119.88 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $100.03 | 2019-2021 | |
| Mylan Specialty L.P. | $97.82 | 2020-2023 | Yupelri |
| La Jolla Pharmaceutical Company | $86.87 | 2019 | |
| Pulmonx Corporation | $84.66 | 2020-2022 | |
| Advanced Respiratory, INC | $80.24 | 2021 | |
| Genzyme Corporation | $71.41 | 2019-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $69.18 | 2022-2023 | Smartvest |
| Genentech USA, INC. | $53.31 | 2019-2023 | Xolair |
| Merck Sharp & Dohme LLC | $30.16 | 2025 | Keytruda |
| Apria Healthcare LLC | $29.92 | 2021 | |
| Nestle Healthcare Nutrition INC. | $27.15 | 2022 | |
| Abbott Laboratories | $24.61 | 2022 | |
| Covidien LP | $23.85 | 2019 | |
| Grifols USA, LLC | $23.38 | 2021 | |
| Inspire Medical Systems, INC. | $22.78 | 2025 | Inspire |
| Kestra Medical Technology Services, INC. | $21.82 | 2022 | |
| Hologic Sales and Service, LLC | $17.57 | 2022 | |
| Gilead Sciences, INC. | $17.00 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $15.14 | 2021 | |
| Evofem Biosciences, INC. | $14.72 | 2022 | |
| Phadia US INC. | $13.60 | 2021 | |
| Novo Nordisk INC | $13.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.